

Date: June 03, 2023

To

The Listing Department

National Stock Exchange of India Limited

Exchange Plaza,

Bandra – Kurla Complex

Bandra (East)

Mumbai - 400 051

Stock Code: INDOCO-EQ

To

The Listing Department

Bombay Stock Exchange Limited

Floor 25, P. J. Towers,

Dalal Street,

Mumbai - 400 001

Stock Code : 532612

Dear Sir/Madam,

<u>Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements)</u>
Regulations, 2015 – Indoco Remedies Limited Goa Plant II- Classified with OAI status

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that United States Food and Drug Administration (USFDA) had inspected Company's Sterile Facility (Plant II) located at Goa("Facility"), from February 20, 2023 to February 28, 2023. The said Facility had 4 observations in Form 483. USFDA has determined the inspection classification of this Facility as OAI (Official Action Indicated).

The Company is committed towards working with USFDA for remediation of the concerns on highest priority.

Commenting on the developments, Ms. Aditi Panandikar, Managing Director, said that "We have done considerable remediation work and shall continue to implement necessary additional corrective actions. We are committed to being cGMP compliant and supplying quality products to our customers and patients across the globe."

Further, we believe that this inspection classification will not have an impact on existing supplies or revenues from this Facility.

You are requested to kindly take the same on record

Thanking you,
Yours faithfully,
For Indoco Remedies Limited

OSO OS NI W THE OSO OS NI W TH

Ramanathan Hariharan Company Secretary & Head- Legal